Teva Pharmaceutical: Generic value

by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

The performance of Teva Pharmaceutical Industries (TEVA) has been disappointing for quite some time now.

Investors have avoided TEVA because its largest selling drug, Copaxone, which treats multiple sclerosis (MS), will meet some new competition from several drug makers within the next few years.